Facts & Figures

Financial year 2018

Owing to continuing high demand and use of capacity in the core segments, both Greiner Bio-One and its suppliers invested significant sums in the enlargement of global production. The bulk of an investment volume of EUR 44.8 million flowed into new production facilities for existing core products. It also represents a platform for further expansion in the core area of blood collection. In addition, the storage space available in Frickenhausen (Germany) was more than doubled. After a construction period of only a year, a new, fully automated high-bay warehouse fitted with the latest storage technology was put into operation thereby replacing the facility used to date. The warehouse is part of an extensive infrastructure project that forms the basis for greater efficiency in the material supply and logistics areas, and will be concluded in 2019 with an increase in production capacity.

The Asian region is one of Greiner Bio-One’s most important growth markets and for example, in China the company has been able to establish a solid position in the preanalytics field within the Beijing area. In October, a second major step followed with the foundation of an additional branch in Shanghai staffed by a focused and specialized team. The joint aim is to step up efforts in the biosciences market and move closer to the customers in this business segment.

In spite of diffcult market circumstances, currency effects and stagnation with regard to individual key accounts and major orders, business volume achieved the level of the preceding year and profitability maintained at an excellent level. In particular, solid growth was achieved in the safety products area and the company gained ground in the regional markets in Southern and Eastern Europe, and South America. However, rising material and raw material prices as well as higher freight costs all served to hinder an even better business development.

In 2016, Greiner Bio-One entered into a successful cooperation with Nano3D Biosciences in Houston (USA) and during 2018 the company acquired the technology assets of this US biotechnology company and thereby moved into the attractive and growing 3D cell culture market. During 2018, the Vigmed company, which was purchased during the previous year, successfully underwent the organizational integration, and developed as planned. On the product side, the intravenous catheters and arterial catheters were also successfully included in the product portfolio.

Greiner Bio-One has extended its range of safety products with an additional safety blood collection set: the VACUETTE® Safety Winged Set. This starter product therefore represents an ideal supplement to the existing VACUETTE® Blood Collection Sets. Also the VACUETTE® CAT Serum Fast Tube and the new VACUETTE® SAFELINK tube holder with integrated Luer-Lock connector came onto the market. In the area of mass cell culture monitoring and analysis, Greiner Bio-One has also decisively enlarged its CELLdisc series portfolio. And for the frozen storage of biological samples in biobanks, Greiner Bio-One now also o.ers Cryo.s refrigeration storage tubes with double coding in the form of a data matrix code together with linear bar code. 

During the 2018 financial year, Greiner Bio-One employed a workforce of 2,301 at 27 locations in 19 countries and attained annual sales revenues of EUR 473 million.


Turnover:

2014 – 2018, figures are given in EUR millions

   2014  2015  2016  20172018
 Turnover 388.0 427.5  452.0 473.0473.0

“We are preparing for further growth through a significant increase in our production capacities.“

Rainer Perneker, CEO Greiner Bio-One International GmbH